Clinical Trial Update: PharmacoEconomic Assessment IRESSA® in the Treatment of Non-Small-Cell Lung Cancer (NSCLC)

View source ↗

Summary

A clinical trial update describing the pharmacoeconomic assessment of IRESSA (gefitinib) for Non-Small Cell Lung Cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Non-Small Cell Lung Cancer | Status: UNKNOWN